Blog

Consilium Strategic Communications Advises BerGenBio on Over-Subscribed €45.4 Million Private Placement

London, 5 May 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised its client, BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, on the international communication of its €45.4 million private placement.

This successful private placement follows the launch of the UK government-funded ACCORD study, where BerGenBio’s lead drug bemcentinib was announced as the first candidate to be fast-tracked for treating the most vulnerable patients with COVID-19. Consilium advised BerGenBio on its international PR and IR activities surrounding the announcement, which saw the value of BerGenBio’s shares rise more than 100% on the day of the news. 

BerGenBio intends to use the net proceeds from the Private Placement to take full advantage of clinical development opportunities stemming from its technology and to progress readiness for early commercialisation possibilities, as well as for general corporate purposes.

“We are delighted to have supported BerGenBio on their strategic communications through their ACCORD trial participation and the successful private placement. The potential of the science has been underlined by the request to test bemcentinib in the ACCORD study and we look forward to continuing to work closely with the team as they progress their whole pipeline.”

Mary-Jane Elliott

Managing Partner of Consilium Strategic Communications

“We are grateful for the support and guidance provided by the Consilium team throughout this exciting and busy time. The team has worked with us to great effect, helping us communicate the BerGenBio story to a wide group of stakeholders and securing significant, impactful international media attention.”

Richard Godfrey

Chief Executive Officer at BerGenBio

The Consilium team representing BerGenBio ASA comprises Mary-Jane Elliott, Chris Welsh, Carina Jurs, Lucy Featherstone and Maya Bennison

BerGenBio’s announcement can be viewed in full here.